← Back to Search

Vestibular Treatment for Concussion

N/A
Waitlist Available
Led By Anthony P Kontos, PhD
Research Sponsored by University of Pittsburgh
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Reported signs of mTBI including: loss of consciousness, amnesia, disorientation, confusion, dizziness, imbalance, memory problems, vomiting
18-50 years of age
Must not have
History of vestibular disorder prior to current mTBI (benign paroxysmal positional vertigo, unilateral or bilateral vestibular hypofunction)
Benign Paroxysmal Positional Vertigo (BPPV) resulting from vestibular hypofunction
Timeline
Screening 3 weeks
Treatment Varies
Follow Up enrollment, 2-week, 4-week, 3-month study visits
Awards & highlights
No Placebo-Only Group

Summary

This trial tests different exercise routines to help people with mild brain injuries who have balance and dizziness issues. The goal is to find the best exercise plan to speed up recovery and improve outcomes. Participants will do these exercises at home and visit the clinic regularly for progress checks.

Who is the study for?
This trial is for individuals aged 18-50 who have had a sports-related mild traumatic brain injury (mTBI) or concussion within the last 8 days to 1 year. They must experience certain symptoms like dizziness, confusion, or balance issues but can't have had vestibular disorders before the mTBI or be currently pregnant.
What is being tested?
The study tests targeted rehabilitation exercises (T-REV) at different intensities and frequencies for treating vestibular symptoms after an mTBI. Participants will do these exercises daily at home and attend weekly clinic visits to adjust their program.
What are the potential side effects?
While not explicitly stated, potential side effects may include increased dizziness, fatigue from exercise, headaches, or discomfort due to the intensity of rehabilitation activities.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have experienced symptoms like confusion, dizziness, or memory problems.
Select...
I am between 18 and 50 years old.
Select...
My vision is normal or corrected to normal.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I had a balance disorder before my recent mild brain injury.
Select...
I have dizziness due to inner ear issues.
Select...
I have a history of a neurological disorder.
Select...
My recent mild brain injury occurred less than a month ago or over six months ago.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~enrollment, 2-week, 4-week, 3-month study visits
This trial's timeline: 3 weeks for screening, Varies for treatment, and enrollment, 2-week, 4-week, 3-month study visits for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Dizziness Handicap Inventory (DHI)
Secondary study objectives
Behavioral Symptom Inventory-18 (BSI-18)
Dizziness Numerical Rating Scale (Dizziness NRS)
Functional Gait Assessment (FGA)
+12 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: Low Intensity/Low FrequencyExperimental Treatment1 Intervention
Participants will be assigned T-REV with low intensity (30% of perceived effort) and low frequency (exercises performed 1x/day)
Group II: Low Intensity/ High FrequencyExperimental Treatment1 Intervention
Participants will be assigned T-REV with low intensity (30% of perceived effort) and high frequency (exercises performed 2x/day)
Group III: High Intensity/Low FrequencyExperimental Treatment1 Intervention
Participants will be assigned T-REV with high intensity (70% of perceived effort) and low frequency (exercises performed 1x/day)
Group IV: High Intensity/High FrequencyExperimental Treatment1 Intervention
Participants will be assigned T-REV with high intensity (70% of perceived effort) and high frequency (exercises performed 2x/day)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
T-REV
2020
N/A
~130

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for vestibular disorders include targeted rehabilitation exercises, which aim to improve vestibular function through specific exercises. These exercises work by promoting neuroplasticity, which helps the brain to adapt and compensate for vestibular deficits. They often involve balance training, gaze stabilization exercises, and habituation exercises that reduce dizziness by gradually exposing patients to the movements that trigger their symptoms. This approach is crucial for patients as it directly addresses the underlying dysfunctions in the vestibular system, leading to improved balance, reduced dizziness, and enhanced overall quality of life.

Find a Location

Who is running the clinical trial?

United States Department of DefenseFED
909 Previous Clinical Trials
333,575 Total Patients Enrolled
University of PittsburghLead Sponsor
1,789 Previous Clinical Trials
16,359,502 Total Patients Enrolled
3 Trials studying Vestibular Disorder
130 Patients Enrolled for Vestibular Disorder
Anthony P Kontos, PhDPrincipal InvestigatorUniversity of Pittsburgh
4 Previous Clinical Trials
166 Total Patients Enrolled
1 Trials studying Vestibular Disorder
50 Patients Enrolled for Vestibular Disorder

Media Library

T-REV Clinical Trial Eligibility Overview. Trial Name: NCT03600324 — N/A
Vestibular Disorder Research Study Groups: High Intensity/High Frequency, High Intensity/Low Frequency, Low Intensity/Low Frequency, Low Intensity/ High Frequency
Vestibular Disorder Clinical Trial 2023: T-REV Highlights & Side Effects. Trial Name: NCT03600324 — N/A
T-REV 2023 Treatment Timeline for Medical Study. Trial Name: NCT03600324 — N/A
~21 spots leftby Nov 2025